Retinal Disease

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Retinal Disease

MalaCards integrated aliases for Retinal Disease:

Name: Retinal Disease 12 15 39
Retinal Diseases 44 15 70
Retinal Disorders 42


External Ids:

Disease Ontology 12 DOID:5679
ICD9CM 34 362.9
MeSH 44 D012164
NCIt 50 C26875
SNOMED-CT 67 29555009
ICD10 32 H35.8 H35.9 H36
UMLS 70 C0035309

Summaries for Retinal Disease

MedlinePlus : 42 The retina is a layer of tissue in the back of your eye that senses light and sends images to your brain. In the center of this nerve tissue is the macula. It provides the sharp, central vision needed for reading, driving and seeing fine detail. Retinal disorders affect this vital tissue. They can affect your vision, and some can be serious enough to cause blindness. Examples are Macular degeneration - a disease that destroys your sharp, central vision Diabetic eye disease Retinal detachment - a medical emergency, when the retina is pulled away from the back of the eye Retinoblastoma - cancer of the retina. It is most common in young children. Macular pucker - scar tissue on the macula Macular hole - a small break in the macula that usually happens to people over 60 Floaters - cobwebs or specks in your field of vision NIH: National Eye Institute

MalaCards based summary : Retinal Disease, also known as retinal diseases, is related to usher syndrome, type iia and aland island eye disease, and has symptoms including eye manifestations An important gene associated with Retinal Disease is GUCY2D (Guanylate Cyclase 2D, Retinal), and among its related pathways/superpathways are Phototransduction and Metabolism of fat-soluble vitamins. The drugs Levoleucovorin and Hydroxocobalamin have been mentioned in the context of this disorder. Affiliated tissues include retina, eye and endothelial, and related phenotypes are nervous system and cardiovascular system

Disease Ontology : 12 An eye disease that is located in the retina.

Wikipedia : 73 The retina (from Latin: rete) is the innermost, light-sensitive layer of tissue of the eye of most... more...

Related Diseases for Retinal Disease

Diseases in the Retinal Disease family:

Inherited Retinal Disorder Rare Retinal Disorder

Diseases related to Retinal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 496)
# Related Disease Score Top Affiliating Genes
1 usher syndrome, type iia 32.4 USH2A MYO7A CEP290 ABCA4
2 aland island eye disease 32.3 RPE65 NR2E3 GUCY2D CACNA1F ABCA4
3 night blindness 32.2 USH2A RPGR RPE65 RHO PRPH2 PRPF31
4 retinal degeneration 32.2 USH2A RPGR RPE65 RHO PRPH2 PDE6B
5 leber plus disease 32.2 USH2A RPGR RPE65 RHO PRPH2 PRPF31
6 vitreoretinochoroidopathy 32.1 RPE65 PRPH2 PRPF31 BEST1 ABCA4
7 cone dystrophy 32.1 USH2A RPGR RPE65 RHO PRPH2 PRPF31
8 enhanced s-cone syndrome 32.1 RPGR RPE65 RHO NR2E3 CRX
9 choroidal dystrophy, central areolar, 1 32.1 RPE65 PRPH2 NR2E3 GUCY2D GUCA1A CRX
10 stargardt disease 32.1 USH2A RPGR RPE65 RHO PRPH2 PRPF31
11 prolonged electroretinal response suppression 32.0 RHO NR2E3 GUCA1A
12 cone dystrophy 3 31.9 RHO GUCA1A
13 retinitis 31.8 USH2A RPGR RPE65 RHO PRPH2 PRPF31
14 yemenite deaf-blind hypopigmentation syndrome 31.7 USH2A RPE65 RHO MYO7A GUCY2D CFH
15 retinitis pigmentosa 31.7 USH2A RPGR RPE65 RHO PRPH2 PRPF31
16 macular degeneration, age-related, 1 31.6 USH2A RPGR RPE65 RHO PRPH2 PRPF31
17 macular retinal edema 31.3 RHO CRB1 CFH BEST1
18 cone-rod dystrophy 2 31.2 USH2A RPGR RPE65 RHO PRPH2 PRPF31
19 retinitis pigmentosa-deafness syndrome 31.2 USH2A MYO7A GUCA1A
20 usher syndrome 31.2 USH2A RPGR RPE65 RHO PRPH2 PRPF31
21 eye disease 31.1 USH2A RPGR RPE65 RHO PRPH2 PDE6B
22 bardet-biedl syndrome 31.0 USH2A RPGR RPE65 RHO PRPH2 PRPF31
23 central serous chorioretinopathy 31.0 CFH ARMS2
24 usher syndrome type 2 31.0 USH2A RPGR RPE65 RHO PRPH2 PDE6B
25 congenital stationary night blindness 31.0 USH2A RPGR RPE65 RHO PRPH2 PRPF31
26 pattern dystrophy 30.9 RHO PRPH2 CRX
27 fundus dystrophy 30.9 USH2A RPGR RPE65 RHO PRPH2 PRPF31
28 stargardt disease 1 30.9 RHO PRPH2 CRX CRB1 BEST1 ABCA4
29 retinoschisis 1, x-linked, juvenile 30.9 USH2A RPGR RPE65 RHO NR2E3 MYO7A
30 pathologic nystagmus 30.9 RPGR RPE65 RHO GUCY2D CRX CRB1
31 achromatopsia 30.9 USH2A RPGR RPE65 RHO PRPH2 PDE6B
32 choroideremia 30.8 USH2A RPGR RPE65 RHO PRPH2 MYO7A
33 usher syndrome, type i 30.8 USH2A RPGR RPE65 RHO PDE6B MYO7A
34 scotoma 30.8 USH2A RPGR RPE65 RHO GUCY2D GUCA1A
35 leber congenital amaurosis 8 30.7 RPE65 GUCY2D CRX CRB1 AIPL1
36 leber congenital amaurosis 13 30.6 CEP290 AIPL1
37 leber congenital amaurosis 12 30.6 RPE65 GUCY2D GUCA1A AIPL1
38 occult macular dystrophy 30.6 RHO PRPH2 GUCY2D ABCA4
39 choroiditis 30.6 CFH ARMS2 ABCA4
40 pigmented paravenous chorioretinal atrophy 30.6 GUCY2D CRB1 AIPL1 ABCA4
41 peripheral retinal degeneration 30.6 RHO PRPH2 CRB1 BEST1 ABCA4
42 leber congenital amaurosis 9 30.6 RPE65 GUCY2D CRX CRB1 CEP290 AIPL1
43 leber congenital amaurosis 3 30.6 RPE65 GUCY2D CRX CRB1 CEP290 AIPL1
44 macular dystrophy, dominant cystoid 30.6 USH2A RPGR RPE65 RHO NR2E3 CRB1
45 leber congenital amaurosis 1 30.6 RPE65 RHO PRPH2 GUCY2D GUCA1A CRX
46 gyrate atrophy of choroid and retina 30.6 RPGR RPE65 RHO PRPH2 BEST1 ABCA4
47 leber congenital amaurosis 7 30.6 GUCY2D CRX CRB1 AIPL1
48 leber congenital amaurosis 16 30.6 GUCY2D CRB1 AIPL1
49 retinitis pigmentosa 7 30.6 RPGR PRPH2 GUCA1A
50 bestrophinopathy, autosomal recessive 30.6 RPE65 PRPH2 CRB1 BEST1 ABCA4

Graphical network of the top 20 diseases related to Retinal Disease:

Diseases related to Retinal Disease

Symptoms & Phenotypes for Retinal Disease

UMLS symptoms related to Retinal Disease:

eye manifestations

MGI Mouse Phenotypes related to Retinal Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.09 ABCA4 AIPL1 CACNA1F CEP290 CFH CRB1
2 cardiovascular system MP:0005385 9.96 ABCA4 CACNA1F CEP290 CFH CRB1 CRX
3 pigmentation MP:0001186 9.77 ABCA4 BEST1 CEP290 CFH CRB1 CRX
4 vision/eye MP:0005391 9.6 ABCA4 AIPL1 BEST1 CACNA1F CEP290 CFH

Drugs & Therapeutics for Retinal Disease

Drugs for Retinal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 343)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
Ranibizumab Approved Phase 4 347396-82-1 459903
Benserazide Approved, Investigational Phase 4 322-35-0
Levodopa Approved Phase 4 59-92-7 6047
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
Dipivefrin Approved Phase 4 52365-63-6 3105
Tropicamide Approved, Investigational Phase 4 1508-75-4 5593
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
Insulin glargine Approved Phase 4 160337-95-1
Phenylephrine Approved Phase 4 59-42-7 6041
Ephedrine Approved Phase 4 299-42-3 9294
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
Pseudoephedrine Approved Phase 4 90-82-4 7028
17 Grape Approved Phase 4
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Fluorouracil Approved Phase 4 51-21-8 3385
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
tannic acid Approved Phase 4 1401-55-4
Fenofibrate Approved Phase 4 49562-28-9 3339
Simvastatin Approved Phase 4 79902-63-9 54454
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
Tesamorelin Approved, Investigational Phase 4 218949-48-5
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
Cobalamin Experimental Phase 4 13408-78-1 6857388
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
40 Vitamin B12 Phase 4
41 Vitamin B 6 Phase 4
42 Vitamin B 12 Phase 4
43 Hematinics Phase 4
44 (T,G)-A-L Phase 4
Glatiramer Acetate Phase 4 147245-92-9 3081884
46 Antiparkinson Agents Phase 4
47 Benserazide, levodopa drug combination Phase 4
48 insulin Phase 4
49 Insulin, Globin Zinc Phase 4
50 Immunoglobulin G Phase 4

Interventional clinical trials:

(show top 50) (show all 646)
# Name Status NCT ID Phase Drugs
1 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
2 Effect of Doxium on High Sensitivity CRP and Endothelin-1 Serum Levels in Patients With Diabetic Retinopathy Unknown status NCT01382498 Phase 4 Calcium dobesilate (Doxium);Placebo drug
3 Different Day Regimes of Preoperative CONbercept Administration on CytokinEs of Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Prospective Randomized Controlled Clinical Trial (CONCEPT) Unknown status NCT03506750 Phase 4 IVC
4 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
5 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
6 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
7 Effects of Glatiramer Acetate (Copaxone) in the Nerve Fiber Layer Thickness and Retinal Function in Diabetic Patients After Pan- Retinal Photocoagulation (PRP), a Double- Masked Randomized Clinical Trial. Unknown status NCT00677664 Phase 4 Glatiramer acetate (Copaxone);Mannitol
8 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
9 CPAP Application at Delivery Room at Very Low Birth Weight Infants Unknown status NCT01024361 Phase 4
10 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
11 Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy. Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
12 Pilot Study Investigating the Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
13 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
14 A 12 Months, Prospective, Multicenter, Open-label, Single Arm Interventional Study Assessing the Safety and Tolerability of 0.5 mg Ranibizumab in Mono/Bilateral Wet AMD Patients in Eyes With (Best-Corrected Distance Visual Acuity) BCVA Below 2/10 and/or Second Affected Eye Completed NCT01986907 Phase 4 ranibizumab
15 Effect of Levodopa on Human Multifocal Electroretinogram Completed NCT00812760 Phase 4 levodopa
16 Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema Completed NCT02646670 Phase 4 Ranibizumab;Aflibercept;Ranibizumab and Aflibercept;Aflibercept and ranibizumab
17 Different Conbercept Injection Methods in Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT02816710 Phase 4 Conbercept
18 Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment. A UK, 18-month, Prospective, Open-label, Multicentre, Single-arm, Phase IIIb Study With 12-month Primary Endpoint, Assessing the Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Diabetic Macular Oedema. Completed NCT01257815 Phase 4 Ranibizumab
19 Topical Application of Latanoprost in Diabetic Retinopathy Completed NCT01225653 Phase 4 Latanoprost
20 Prospective, Single-center, Six-month Study of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy: Effects on Microaneurysm Turnover and Non-perfused Retinal Area Completed NCT02834663 Phase 4 Lucentis
21 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Using a Semiautomated Patterned Scanning Laser System in Proliferative Retinopathy or Macular Edema Secondary to Diabetes Mellitus or Retinal Vein Occlusion Completed NCT00682240 Phase 4
22 Sucrose and Non Nutritive Suck as Analgesia for Babies Undergoing Retinopathy of Prematurity Screening; a Randomised Placebo Controlled Trial Completed NCT00921544 Phase 4
23 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
24 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4 Bevacizumab
25 Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage IV and V Completed NCT00563121 Phase 4
26 Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage V. Completed NCT00500396 Phase 4
27 Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy With New Dense Vitreous Hemorrhage After Full Panretinal Photocoagulation Completed NCT01724385 Phase 4 intravitreal injection of bevacizumab
28 Effects of Fenofibrate on Endothelial Progenitor Cell Levels in Diabetic Patients With Retinopathy. A Randomized Controlled Trial. Completed NCT01927315 Phase 4 Fenofibrate 145 mg;Placebo
29 Investigator Initiated Observational Study of Intravitreal Aflibercept Injection in Subjects With Diabetic Macular Edema Previously Treated With Ranibizumab or Bevacizumab Completed NCT02559180 Phase 4 aflibercept
30 Evaluation of Diabetic Retinopathy Progression in Subjects With Type 2 Diabetes Mellitus Treated With Insulin Completed NCT00174824 Phase 4 Insulin glargine
31 Efficacy and Safety of Mydriatic Microdrops Compared With Standard Drops for Retinopathy of Prematurity (ROP) Screening: a Pilot Randomized Clinical Trial Completed NCT04623684 Phase 4 Microdrop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 6-7 μL)];Standard drop administration [phenylephrine 1.67% + tropicamide 0.33% (drop volume: 28-34 μL)]
32 DECREASING THE NEED FOR MECHANICAL VENTILATION AFTER RETINOPATHY OF PREMATURITY SURGERY: Sedation vs General Anesthesia Completed NCT01955135 Phase 4 Ketamine;Sevoflurane;propofol
33 Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
34 A Multicenter, Randomized, Double-blind Non-inferiority Trial to Evaluate the Efficacy and Safety of Entelon® as Compared to Doxium Tab. And Placebo for the Treatment of Nonproliferative Diabetic Retinopathy Completed NCT03962296 Phase 4 Vitis vinifera extract;Calcium Dobesilate;Placebo
35 Comparison of the Vascular Endothelial Growth Factor Serum Concentrations After Intravitreal Use of Bevacizumab or Ranibizumab as a Treatment for Type 1 Retinopathy of Prematurity Completed NCT03148132 Phase 4 Bevacizumab Injection;Ranibizumab Ophthalmic
36 A Randomised Placebo-controlled Trial of Fenofibrate to Prevent Progression of Non-proliferative Retinopathy in Diabetes Recruiting NCT03439345 Phase 4 Fenofibrate 145 mg;Placebo Oral Tablet
37 Macular Perfusion Changes in Proliferative Diabetic Retinopathy Following Anti-VEGF Therapy Versus Targeted and Pan-retinal Photocoagulation Using Optical Coherence Tomography Angiography Recruiting NCT04674254 Phase 4 Bevacizumab Injection
38 Increase in Capillary Plexus Density Level Following the Use of Ozurdex for the Treatment of DME (RMSM ICOD STUDY) Recruiting NCT04038125 Phase 4 Ozurdex Drug Implant Product
39 DEXTENZA VS. PREDNISOLONE ACETATE 1% in the Incidence of Pseudophakic Macular Edema in Patients With Diabetic Retinopathy Undergoing Cataract Surgery Recruiting NCT04362241 Phase 4 Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
40 Effect of Continuous Positive Airway Pressure on the Progression of Vascular Retinal Disease in Patients With Sleep Apnea and Non-proliferative Diabetic Retinopathy. A Randomized Clinical Trial Active, not recruiting NCT02874313 Phase 4 Pharmacological treatment
41 A Phase IV Randomised Clinical Trial of Laser Therapy for Peripheral Retinal Ischaemia Combined With Intravitreal Aflibercept (Eylea®) Versus Intravitreal Aflibercept Monotherapy for Diabetic Macular Oedema Active, not recruiting NCT02432547 Phase 4 Aflibercept
42 Outpatient Performed Pterygium Surgery Study Not yet recruiting NCT03037736 Phase 4 5-Fluorouracil;Bevacizumab;Normal saline
43 Efficacy of Calcium Dobesilate in Treating Chinese Patients With Mild to Moderate Non-proliferative Diabetic Retinopathy (CALM-DR): a Single-blind, Multicenter, Cluster-randomized, Controlled Trial Not yet recruiting NCT04283162 Phase 4 Calcium Dobesilate
44 Prospective, Single-blind, Randomised, Controlled, Multi-centre Study to Evaluate the Benefit of Ranibizumab as an Adjunctive Therapy to Vitrectomy for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Oedema Not yet recruiting NCT04464694 Phase 4 Ranibizumab
45 Evaluation of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients Not yet recruiting NCT04140201 Phase 4 Simvastatin 40mg;Fenofibrate 200mg;Omega 3 fatty acid
46 Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial Not yet recruiting NCT04708145 Phase 4 Aflibercept Injection
47 The Evaluation of Retinal PhotoReceptors And Vasculature in Moderate and Severe Non-proliferative Diabetic Retinopathy Patients After Intravitreal Aflibercept on Using Adaptive Optics Imaging Study (PRAVA) Study Not yet recruiting NCT04702048 Phase 4 Aflibercept Injection;Sham injection
48 A 52-week, Two Arm, Randomized, Open-label, Multicenter Study Assessing the Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens for Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration Not yet recruiting NCT04679935 Phase 4
49 Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity Terminated NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo
50 A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes Terminated NCT01591902 Phase 4 Tesamorelin;Placebo-Control

Search NIH Clinical Center for Retinal Disease

Cochrane evidence based reviews: retinal diseases

Genetic Tests for Retinal Disease

Anatomical Context for Retinal Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Retinal Disease:


MalaCards organs/tissues related to Retinal Disease:

Retina, Eye, Endothelial, Bone Marrow, Bone, Skin, Brain

Publications for Retinal Disease

Articles related to Retinal Disease:

(show top 50) (show all 5550)
# Title Authors PMID Year
Macular diseases in Ibadan, Nigeria. 42
33723107 2021
Profile of patients receiving intravitreal anti-vascular endothelial growth factor injections during COVID-19-related lockdown. 42
33595512 2021
Short term visual and structural outcomes of anti-vascular endothelial growth factor (anti-VEGF) treatment delay during the first COVID-19 wave: A pilot study. 42
33596257 2021
Luteolin delays photoreceptor degeneration in a mouse model of retinitis pigmentosa. 61
33642401 2021
The neuroprotective role of Wnt signaling in the retina. 61
33433466 2021
OFF bipolar cell density varies by subtype, eccentricity, and along the dorsal ventral axis in the mouse retina. 61
33135176 2021
The inducible nitric oxide synthase-inhibitor 1400W as a potential treatment for retinal diseases. 61
33269785 2021
Müller Glia-Mediated Retinal Regeneration. 61
33417229 2021
Mutant three-repeat tau expression initiates retinal ganglion cell death through Caspase-2. 61
33516874 2021
The therapeutic use of quercetin in ophthalmology: recent applications. 61
33561647 2021
Drug-related adverse effects of antivascular endothelial growth factor agents. 61
33770015 2021
Co-delivery of glial cell-derived neurotrophic factor (GDNF) and tauroursodeoxycholic acid (TUDCA) from PLGA microspheres: potential combination therapy for retinal diseases. 61
33641047 2021
Involvement of TRPM2 Channel on Hypoxia-Induced Oxidative Injury, Inflammation, and Cell Death in Retinal Pigment Epithelial Cells: Modulator Action of Selenium Nanoparticles. 61
33389617 2021
Mammalian Retinal Cell Quantification. 61
33380270 2021
Taurine and oxidative stress in retinal health and disease. 61
33621439 2021
Ferrostatin-1 attenuates ferroptosis and protects the retina against light-induced retinal degeneration. 61
33631670 2021
Transcriptome Landscape of Epithelial to Mesenchymal Transition of Human Stem Cell-Derived RPE. 61
33792620 2021
32956210 2021
32804831 2021
A detailed and comparative work for retinal vessel segmentation based on the most effective heuristic approaches. 61
33768764 2021
Ubiquitous Chromatin Modifiers in Congenital Retinal Diseases: Implications for Disease Modeling and Regenerative Medicine. 61
33573910 2021
Imaging the pediatric retina: An overview. 61
33727440 2021
Investigational neuroprotective compounds in clinical trials for retinal disease. 61
33641585 2021
Updating the Staging System for Diabetic Retinal Disease. 61
33218709 2021
Quantification of BNN27, a novel neuroprotective 17-spiroepoxy dehydroepiandrosterone derivative in the blood and retina of rodents, after single intraperitoneal administration. 61
33638308 2021
A New Era in Reducing Treatment Burden in Retinal Disease. 61
33787534 2021
Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision. 61
33604870 2021
Diagnosis of Inherited Retinal Diseases. 61
33784788 2021
Derivation of Induced Pluripotent Stem Cell (iPSC) Lines from Patient-Specific Peripheral Blood Mononuclear Cells (PBMC) Using Episomal Vectors. 61
33772463 2021
Panel-based genetic testing for inherited retinal disease screening 176 genes. 61
33749171 2021
First 3D-Structural Data of Full-Length Guanylyl Cyclase 1 in Rod-Outer-Segment Preparations of Bovine Retina by Cross-Linking/Mass Spectrometry. 61
33744315 2021
The Potential Application of Pentacyclic Triterpenoids in the Prevention and Treatment of Retinal Diseases. 61
33761574 2021
Migration of pre-induced human peripheral blood mononuclear cells from the transplanted to contralateral eye in mice. 61
33691753 2021
Genome-Editing Strategies for Treating Human Retinal Degenerations. 61
32993386 2021
Complete congenital stationary night blindness associated with a novel NYX variant (p.Asn216Lys) in middle-aged and older adult patients. 61
33769208 2021
Mesenchymal Stem Cell-Based Therapy for Retinal Degenerative Diseases: Experimental Models and Clinical Trials. 61
33799995 2021
Gene therapy for inherited retinal diseases: progress and possibilities. 61
33689657 2021
Apparent but unconfirmed digenism in an Iranian consanguineous family with syndromic Retinal Disease. 61
33741323 2021
Deep learning-based classification of retinal atrophy using fundus autofluorescence imaging. 61
33383315 2021
The impact of macular edema on microvascular and metabolic alterations in retinitis pigmentosa. 61
32910309 2021
Retinitis pigmentosa is associated with shifts in the gut microbiome. 61
33758301 2021
The role of sirt1 in the retinal ganglion cells cultured by high glucose. 61
33174070 2021
Uptake and Distribution of Administered Bone Marrow Mesenchymal Stem Cell Extracellular Vesicles in Retina. 61
33806128 2021
Neurodegeneration, Neuroprotection and Regeneration in the Zebrafish Retina. 61
33809186 2021
Visual Acuity Variability: Comparing Discrepancies between Snellen and ETDRS Measurements among Subjects Entering Prospective Trials. 61
32595096 2021
A critical review: Psychophysical assessments of diabetic retinopathy. 61
32866468 2021
The stress response protein REDD1 as a causal factor for oxidative stress in diabetic retinopathy. 61
33524531 2021
Inherited retinal diseases: Therapeutics, clinical trials and end points-A review. 61
33686777 2021
Retinal nonperfusion in optical coherence tomography angiography. 61
33453421 2021
Fabrication and Characterisation of a Photo-Responsive, Injectable Nanosystem for Sustained Delivery of Macromolecules. 61
33805969 2021

Variations for Retinal Disease

Expression for Retinal Disease

Search GEO for disease gene expression data for Retinal Disease.

Pathways for Retinal Disease

GO Terms for Retinal Disease

Cellular components related to Retinal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell projection GO:0042995 9.92 USH2A RPGR RHO PRPH2 GUCY2D GUCA1A
2 photoreceptor inner segment GO:0001917 9.56 USH2A RHO PRPH2 MYO7A GUCA1A CRB1
3 photoreceptor disc membrane GO:0097381 9.55 RHO PDE6B GUCY2D GUCA1A ABCA4
4 photoreceptor connecting cilium GO:0032391 9.54 USH2A MYO7A CEP290
5 photoreceptor outer segment membrane GO:0042622 9.43 RHO PDE6B GUCY2D
6 photoreceptor outer segment GO:0001750 9.32 RPGR RHO PRPH2 PDE6B MYO7A GUCY2D

Biological processes related to Retinal Disease according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 response to stimulus GO:0050896 9.8 USH2A RPGR RPE65 RHO PRPH2 PDE6B
2 photoreceptor cell maintenance GO:0045494 9.73 USH2A RHO CRB1 ABCA4
3 retina development in camera-type eye GO:0060041 9.73 RPE65 RHO PRPH2 PDE6B NR2E3 CRB1
4 regulation of rhodopsin mediated signaling pathway GO:0022400 9.72 RHO PDE6B GUCY2D GUCA1A AIPL1
5 retinoid metabolic process GO:0001523 9.71 RPE65 RHO ABCA4
6 eye photoreceptor cell development GO:0042462 9.71 NR2E3 MYO7A CRB1 CEP290
7 retina homeostasis GO:0001895 9.69 RPE65 ARMS2 AIPL1
8 phototransduction, visible light GO:0007603 9.67 RHO PDE6B AIPL1 ABCA4
9 phototransduction GO:0007602 9.65 RHO NR2E3 GUCA1A
10 sensory perception of light stimulus GO:0050953 9.63 USH2A RHO MYO7A
11 cellular response to light stimulus GO:0071482 9.58 RHO CRB1
12 photoreceptor cell outer segment organization GO:0035845 9.57 PRPH2 CRB1
13 retina morphogenesis in camera-type eye GO:0060042 9.56 RPE65 CRB1
14 rhodopsin mediated signaling pathway GO:0016056 9.55 RHO PDE6B
15 detection of light stimulus involved in visual perception GO:0050908 9.55 RPE65 PRPH2 CRB1 CACNA1F BEST1
16 visual perception GO:0007601 9.53 USH2A RPGR RPE65 RHO PRPH2 PDE6B
17 inner ear receptor cell differentiation GO:0060113 9.52 USH2A MYO7A
18 detection of light stimulus GO:0009583 9.49 RHO PDE6B

Sources for Retinal Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....